CIRM Clinical Trials
Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization. Visit our Funding Opportunities page to apply for clinical trial research funding.
0
CIRM-Funded Clinical Trials
Disease Areas | Investigator | Organization | Phase | Trial Status | Target Enrollment | Detail |
---|---|---|---|---|---|---|
Solid Tumors | Dr. John Le Gall | Allogene Therapeutics | Phase 1 | Launching | N/A | |
Neurological Disorders | Amit Etkin | Alto Neuroscience | Phase 2 | Launching | N/A | |
Blood Cancer | Dr. Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1 | Completed | 10 | |
Blood Cancer | Dr. Edward Kavalerchik | Angiocrine Bioscience, Inc. | Phase 1/2 | Completed | 42 | |
B cell cancers | Dr. Paul Finnegan | Angiocrine Bioscience, Inc. | Phase 3 | Closed | 130 | |
Parkinson's Disease | Dr. Edward Wirth III | Aspen Neuroscience | Phase 1 | Launching | N/A | |
Solid Tumors | Dr. Pamela Reilly Contag | BioEclipse Therapeutics INC. | Phase 1 | Recruiting | 60 | |
Sickle Cell Disease | David Williams | Boston Children’s Hospital | Phase 2 | Recruiting | 25 | |
Parkinson's Disease | Krystof S. Bankiewicz | Brain Neurotherapy Bio | Phase 1 | Active, not recruiting | 11 | |
Amyotrophic Lateral Sclerosis | Dr. Ralph Kern | BrainStorm Cell Therapeutics | Phase 3 | Completed | 196 | |
Melanoma | Robert Dillman | Caladrius Biosciences | Phase 3 | Closed | 4 | |
Type 1 diabetes | Dr. William Sietsema | Caladrius Biosciences | Phase 2 | Completed | 113 | |
Arthritis Osteoarthritis |
Dr. Kristen A Johnson | Calibr | Phase 1 | Completed | 60 | |
HIV/AIDS | Geoff Symonds | Calimmune, Inc. | Phase 1/2 | Completed | 13 | |
Heart failure | Dr. Rachel Ruckdeschel Smith | Capricor, Inc | Phase 2 | Closed | 135 | |
Heart disease associated with Duchenne muscular dystrophy | Dr. Linda Marban | Capricor, Inc | Phase 2 | Completed | 25 | |
Amyotrophic Lateral Sclerosis | Professor Clive Niels Svendsen | Cedars-Sinai Medical Center | Phase 1/2 | Completed | 18 | |
Pulmonary Hypertension Vascular Disease |
Dr. Michael I Lewis | Cedars-Sinai Medical Center | Phase 1/2 | Completed | 26 | |
Retinitis Pigmentosa | Clive Svendsen | Cedars-Sinai Medical Center | Phase 1 | Recruiting | 16 | |
Amyotrophic Lateral Sclerosis | Clive Svendsen | Cedars-Sinai Medical Center | Phase 1 | Launching | N/A | |
COVID-19 Respiratory Disorders |
William van der Touw | Celularity Inc. | Phase 1/2 | Unknown status | 86 | |
Blood Cancer Bone Marrow Transplant and Viral Infection |
Michael A. Pulsipher | Children’s Hospital of Los Angeles | Phase 1/2 | Active, not recruiting | 60 | |
Brain Cancer | Dr. Christine E. Brown | City of Hope, Beckman Research Institute | Phase 1 | Active, not recruiting | 82 | |
HIV/AIDS | Prof. John A. Zaia | City of Hope, Beckman Research Institute | Phase 1 | Active, not recruiting | 12 | |
Sickle Cell Disease | Dr. De-Fu Zeng | City of Hope, Beckman Research Institute | Phase 1 | Active, not recruiting | 3 | |
Brain Cancer Breast Cancer |
Dr Saul J Priceman | City of Hope, Beckman Research Institute | Phase 1 | Recruiting | 39 | |
COVID-19 Respiratory Disorders |
Prof. John A. Zaia | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Brain Cancer | Dr. Leo D Wang | City of Hope, Beckman Research Institute | Phase 1 | Recruiting | 18 | |
Brain Cancer | Dr Jana Portnow | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Anemia | Ryotaro Nakamura | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
HIV/AIDS | Dr. Angelo Manuel Almeida Cardoso Ph.D., MD | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Leukemia, Acute Myeloid (AML) | Elizabeth Budde | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Corneal Damage | R. Kim Brazzell | Combangio, Inc. | Phase 2 | Launching | N/A | |
Solid Tumors | Pei Wang | Eureka Therapeutics, Inc. | Phase 1/2 | Launching | N/A | |
Sickle Cell Disease | Dr Pierre Caudrelier | ExCellThera Inc. | Phase 1 | Withdrawn | N/A | |
HIV/AIDS | William Kennedy | Excision BioTherapeutics | Phase 1 | Active, not recruiting | 6 | |
Lupus, Systemic Lupus Erythematosus (SLE) | Bob Valamehr | Fate Therapeutics, Inc. | Phase 1 | Launching | N/A | |
Leukemia, Acute Myeloid (AML) | Mark Chao | Forty Seven Inc. | Phase 1 | Closed | 258 | |
Colon Cancer | Mark Chao | Forty Seven Inc. | Phase 1/2 | Completed | 78 | |
Osteoarthritis | Dr. Thomas W Chalberg Jr. | Genascence Corporation | Phase 1 | Launching | N/A | |
Spinal Cord Injury | Dr. Jane Stephanie Lebkowski Dr. | Geron Corporation | Phase 1 | Completed | 5 | |
Kidney Failure | Jeffrey Lawson | Humacyte, Inc. | Phase 3 | Active, not recruiting | 240 | |
Kidney Failure | Jeffrey Lawson | Humacyte, Inc. | Phase 3 | Completed | 355 | |
Immune Disease | DR Jonathan Benjamin | ImmPACT-Bio, Inc. | Phase 1/2 | Launching | N/A | |
Leukemia, Acute Myeloid (AML) | Joseph Paul Woodard | Immune-Onc Therapeutics | Phase 1 | Recruiting | 106 | |
Brain Cancer | Anthony J. Gringeri | ImmunoCellular Therapeutics | Phase 3 | Suspended | 234 | |
Bone or Cartilage Disease Hearing Loss Intellectual Disability Metabolic Disorders Vision Loss |
Dr Robert Hayes | Immusoft Corporation | Phase 1 | Launching | N/A | |
Immune Disease Pediatrics Severe Combined Immunodeficiency, X-linked (X-SCID) |
Dr. Judith A Shizuru Wendy Pang |
Stanford University Jasper Therapeutics, Inc. |
Phase 1/2 | Recruiting | 40 | |
Retinitis Pigmentosa | Henry John Klassen | jCyte, Inc | Phase 2 | Completed | 84 | |
Retinitis Pigmentosa | Henry John Klassen | jCyte, Inc | Phase 2 | Completed | 84 | |
Spinal Cord Injury | Francois Binette | Lineage Cell Therapeutics, Inc. | Phase 1/2 | Completed | 25 | |
Age-related macular degeneration | Dr. Jeffrey H Stern | Luxa Biotechnology | Phase 1/2 | Launching | N/A | |
Kidney Failure | Daniel Brennan | Medeor Acquisition Corp. | Phase 3 | Completed | 30 | |
Epilepsy | Dr. Cory R Nicholas | Neurona Therapeutics | Phase 1 | Recruiting | 40 | |
Blood Disorders | Ilya Rachman MD PhD | Nexcella, Inc. | Phase 1 | Launching | N/A | |
Leukemia, Acute Myeloid (AML) | Dr. Colleen Delaney | Nohla Therapeutics Inc | Phase 2 | Closed | 146 | |
Genetic Disorder Immune Disease Pediatrics Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Dr. Donald B Kohn Leslie Meltzer Dr. Donald B. Kohn PhD |
University of California, Los Angeles Orchard Therapeutics plc |
Phase 2 | Completed | 10 | |
Multiple Myeloma | Rajesh Belani MD | Poseida Therapeutics, Inc. | Phase 1 | Closed | 105 | |
Age-related macular degeneration | Dr Jane S Lebkowski | Regenerative Patch Technologies LLC | Phase 2 | Launching | N/A | |
Immune Disease Leukocyte Adhesion Deficiency |
Dr. Kinnari Patel | Rocket Pharmaceuticals, Inc. | Phase 1/2 | Completed | 9 | |
Bone or Cartilage Disease | Dr. Gayatri Rao | Rocket Pharmaceuticals, Inc. | Phase 1 | Closed | 1 | |
Danon Disease Pediatrics |
Dr. Jonathan Schwartz | Rocket Pharmaceuticals, Inc. | Phase 2 | Launching | N/A | |
Stroke | Dr. Bijan Nejadnik | SanBio, Inc. | Phase 2 | Completed | 163 | |
Beta Thalassemia | Bettina Cockroft | Sangamo BioSciences, Inc. | Phase 1/2 | Completed | 5 | |
Leukemia, Acute Myeloid (AML) | Rochelle Emery | Senti Biosciences, Inc. | Phase 1 | Launching | N/A | |
Immune Disease Severe Combined Immunodeficiency, X-linked (X-SCID) |
Stephen Gottschalk | St. Jude Children’s Research Hospital | Phase 1/2 | Suspended | 28 | |
Blood Cancer Solid Tumors |
Professor Irving L Weissman MD | Stanford University | Phase 1 | Completed | 88 | |
Kidney Failure | Dr Robert Lowsky | Stanford University | Phase 1 | Active, not recruiting | 15 | |
B cell cancers Leukemia |
Dr. David B. Miklos | Stanford University | Phase 1 | Active, not recruiting | 56 | |
Kidney Failure | Dr. Everett H. Meyer | Stanford University | Phase 1 | Recruiting | 22 | |
Stroke | Dr. Gary Steinberg | Stanford University | Phase 1 | Recruiting | 30 | |
Brain Cancer | Crystal Mackall | Stanford University | Phase 1 | Recruiting | 54 | |
B cell cancers Leukemia Leukemia, Acute Myeloid (AML) |
Dr. Matthew H Porteus | Stanford University | Phase 1 | Recruiting | 22 | |
Heart failure | Dr. Joseph C. Wu | Stanford University | Phase 1 | Recruiting | 18 | |
IPEX Syndrome | Dr. Rosa Bacchetta | Stanford University | Phase 1 | Recruiting | 30 | |
Anemia Bone Marrow Transplant and Viral Infection |
Alice Bertaina | Stanford University | Phase 1/2 | Launching | N/A | |
Anemia | Dr. Matthew H Porteus | Stanford University | Phase 1/2 | Launching | N/A | |
Brain Cancer | Dr. Reena Parada Thomas | Stanford University | Phase 1 | Launching | N/A | |
Melanoma | Anusha Kalbasi | Stanford University | Phase 1 | Launching | N/A | |
Colon Cancer | Ivan King | Tachyon Therapeutics, Inc | Phase 1 | Launching | N/A | |
Huntington's Disease | Dr. Vicki Wheelock | University of California, Davis | Phase 1/2 | Completed | 29 | |
HIV-related Lymphoma HIV/AIDS |
Dr Mehrdad Abedi | University of California, Davis | Phase 1/2 | Active, not recruiting | 11 | |
Osteonecrosis | Nancy E. Lane | University of California, Davis | Phase 1/2 | Completed | 58 | |
Developmental Disorders Spina Bifida |
Dr. Diana L. Farmer | University of California, Davis | Phase 2 | Recruiting | 55 | |
Muscle Injury | Peter C Belafsky | University of California, Davis | Phase 1/2 | Recruiting | 62 | |
Retinitis Pigmentosa | Dr. Henry John Klassen | University of California, Irvine | Phase 1/2 | Completed | 28 | |
Melanoma Skin cancer |
Dr. Antoni Ribas MD/PhD | University of California, Los Angeles | Phase 1 | Closed | 5 | |
Immune Disease Pediatrics X-linked Chronic Granulomatous Disease |
Dr. Donald B. Kohn PhD | University of California, Los Angeles | Phase 1/2 | Recruiting | 16 | |
Pediatrics Sickle Cell Disease |
Dr. Donald B. Kohn PhD | University of California, Los Angeles | Phase 1 | Active, not recruiting | 4 | |
Solid Tumors | Dr. Dennis J Slamon | University of California, Los Angeles | Phase 1 | Completed | 46 | |
Lung Cancer | Dr. Steven M. Dubinett MD | University of California, Los Angeles | Phase 1 | Active, not recruiting | 24 | |
Sarcoma | Theodore Scott Nowicki | University of California, Los Angeles | Phase 1 | Closed | 5 | |
Corneal Damage | Dr. Sophie X Deng | University of California, Los Angeles | Phase 1 | Recruiting | 20 | |
B cell cancers Leukemia |
Thomas J Kipps | University of California, San Diego | Phase 1/2 | Active, not recruiting | 102 | |
Blood Cancer | Thomas J Kipps | University of California, San Diego | Phase 1 | Completed | 26 | |
Cystinosis Kidney Failure |
Dr. Stephanie Cherqui | University of California, San Diego | Phase 1/2 | Active, not recruiting | 6 | |
Neurological Disorders Other |
Prof. Olivia Kim-McManus | University of California, San Diego | Phase 1/2 | Launching | N/A | |
Alpha Thalassemia Major | Dr. Tippi C. MacKenzie | University of California, San Francisco | Phase 1 | Enrolling by invitation | 10 | |
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) | Mort Cowan | University of California, San Francisco | Phase 1 | Recruiting | 25 | |
Type 1 diabetes | Peter Stock | University of California, San Francisco | Phase 1/2 | Recruiting | 8 | |
COVID-19 | Dr. Michael Matthay MD | University of California, San Francisco | Phase 2 | Completed | 120 | |
HIV/AIDS Immune Disease |
Steven G. Deeks | University of California, San Francisco | Phase 1/2 | Recruiting | 18 | |
Sickle Cell Disease | Mark C. Walters M.D. | University of California, San Francisco | Phase 1 | Not yet recruiting | 9 | |
Brain Cancer | Dr. Hideho Okada | University of California, San Francisco | Phase 1 | Launching | N/A | |
Brain Cancer | Noriyuki Kasahara | University of California, San Francisco | Phase 1 | Launching | N/A | |
Age-related macular degeneration | Dr. Mark S Humayun | University of Southern California | Phase 1 | Unknown status | 16 | |
Type 1 diabetes | Howard Foyt | ViaCyte, Inc. | Phase 1/2 | Closed | 19 | |
Type 1 diabetes | Manasi Jaiman | ViaCyte, Inc. | Phase 1/2 | Completed | 49 | |
Bladder or Urinary Tract Disorder | James Yoo | Wake Forest University Health Sciences | Phase 1 | Not yet recruiting | 10 |